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Abstract Diabetes and periodontitis are chronic inflamma-
tory disorders that contribute to each others’ severity and
worsen each others’ prognosis. Studies have shown that
patients with diabetes are at increased risk of developing
periodontitis, and that diabetics with untreated periodontitis
have more difficulty controlling serum glucose. Periodontal
treatment that reduces gingival inflammation aids in the
control of hyperglycemia. Periodontitis is accompanied by
gingival bleeding and the production of an inflammatory
exudate termed gingival crevicular fluid (GCF) that arises
from the inflamed gingival tissues surrounding the teeth.
GCF contains byproducts of connective tissue degradation,
enzymes from host and bacterial cells, cytokines and other
inflammatory mediators, and has been studied for screening
blood glucose and for biomarkers of both diabetes and
periodontitis. This review focuses on the inter-relationship
between diabetes and periodontitis and the biomarkers
common to both these diseases that may enable earlier
detection, targeted preventive measures and individualized
therapeutic intervention of these chronic conditions.
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Introduction
The identification and utilization of diagnostic biomarkers
of various disease states has been advocated as a means of
simplifying or improving the accuracy and efficiency of
diagnostic procedures. In 2001, an NIH working group
standardized the definition of a biomarker as “a character-
istic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes,
or pharmacologic responses to a therapeutic intervention” [1].
Improved diagnostic efforts resulting from the utilization of
novel biomarkers should enable optimal treatment planning
and a more focused prevention of common human patholo-
gies. Such biomarkers could also be used to screen healthy
patients and identify those who may be predisposed to
potential pathologies later in life and thereby enable the
clinician to implement well-timed preventive measures. For
the last two decades efforts have been made to identify
biomarkers for diabetes mellitus and periodontitis. Diabetes
and periodontitis are chronic inflammatory diseases which
share a number of pathogenic mechanisms with common
inflammatory mediators which have been investigated as
possible biomarkers of disease status. This review describes
the relationship between diabetes mellitus and periodontitis
and summarizes the research aimed at the identification of
biomarkers for these two diseases.
Diabetes mellitus (DM) is a group of disorders associ-
ated with a quantitative reduction in insulin production or a
qualitative reduction in the action of insulin leading to
changes in carbohydrate, protein, and lipid metabolism [2]
and accumulation of glucose in the bloodstream. Increased
glucose in the bloodstream results in hyperglycemia which
affects a variety of tissues and organ systems including
eyes, nerves, kidneys, and blood vessels. The periodontal
tissues are also affected as a result of hyperglycemia, and
periodontitis has been described as the sixth complication
of diabetes mellitus [3].
The public health burden of diabetes in the world is
enormous and many of the people suffering from diabetes
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are unaware of the problem. The most common types of
diabetes include type 1, type 2, and gestational diabetes,
although some other forms also exist. Type 1 DM is caused
by the destruction of β-cells in the pancreatic islets of
Langerhans [4] and most often occurs in children and
young adults. Type 2 DM usually occurs in adults, but may
also been seen in children and young adults and is the more
common form of DM. This is also the form of DM that is
most commonly encountered in the dental office. Type 2
DM is a chronic condition and unlike type 1 DM, can
remain undiagnosed for a long time and may in fact be first
recognized by a dental care provider. Type 2 DM is
characterized by increased glucose production in the liver
and increased peripheral resistance to insulin in the muscles
and a subsequent reduction in insulin secretion. Exercise and
weight loss improve insulin sensitivity in these patients
and decrease insulin sensitivity in the peripheral tissues.
Medications are often used to improve carbohydrate
metabolism, increase pancreatic insulin production, or
decrease insulin resistance. Sometimes, insulin is adminis-
tered to improve glycemic state in type 2 DM as well.
Gestational diabetes occurs mostly in women in their third
trimester of pregnancy and results in significant perinatal
morbidity and mortality. Most patients with gestational
diabetes return to their normal glycemic state after delivery
although these women have been shown to be more likely
to develop diabetes at a later age.
The major systemic complications and the resulting
morbidity and mortality associated with diabetes has been
attributed to a sustained state of hyperglycemia in the
diabetic subject which leads to micro- and macrovascular
complications and eventual damage to the structure and
function within several major organ systems. In the large
blood vessels, diabetes is associated with an increase in
lipid deposition, thickening of arterial walls, and atheroma
formation. Microvascular complications are due to damage
of endothelial cells and alterations in endothelial basement
membranes [2].
Diabetes has several effects on the oral cavity including
xerostomia (reduced salivary flow), burning mouth, altered
wound healing, and increased incidence of periodontal
diseases such as gingivitis and periodontitis. Clinical
studies have established that periodontal diseases are more
prevalent and of greater severity in patients with type 1 or
type 2 diabetes than in non-diabetic patients [5–9]. In
addition, the prevalence and severity of gingival inflamma-
tion and bleeding within diabetic patients has been shown
to be directly related to their level of metabolic control
[10–15]. In fact, a strong positive association has been
demonstrated between elevated HbA1c levels over a 2-year,
pre-examination period and the presence and severity of
periodontitis [16], and several studies have suggested a
dose-response relationship between poor metabolic control
and the severity of periodontitis [17–19]. In addition
periodontal pockets with probing attachment loss occur
more frequently in diabetics [20]; diabetics with more
advanced systemic complications have more severe perio-
dontitis [21]; and poorly controlled diabetics respond less
favorably to periodontal treatment [22].
The normal human periodontium
The tissues that anchor the teeth and support them during
health and function constitute the periodontium (Greek
peri, “around”; odont, “tooth”) and include the gingiva
(Fig. 1), which covers the maxillary and mandibular
alveolar bone, and the periodontal attachment apparatus
(Fig. 2) which attaches the tooth to the jaw and includes
cementum, periodontal ligament, and alveolar bone [23]
(Fig. 3). In the normal periodontium, the gingiva surrounds
the neck of each tooth, much like a collar. There is normally
a shallow 2 to 3 mm space formed between the margin of
the gingiva and the crown of the tooth where the gingiva
overlaps a portion of the crown of the tooth [23]. This space
between the crown of the tooth and the gingival tissue is the
gingival sulcus (Fig. 4).
The periodontal attachment apparatus is the means by
which the tooth is attached to the jaw and consists of the
cementum on the root of the tooth, the alveolar bone lining
Fig. 1 Teeth surrounded by
healthy periodontium
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the tooth socket and the periodontal ligament (Figs. 2
and 3). Cementum is a mineralized connective tissue that
covers the roots of the teeth and its main function is to
attach the periodontal ligament fibers to the teeth. It is
similar in structure to bone, but differs from it in its
microscopic organization, lack of vascularity, and the
absence of continuous remodeling. The periodontal liga-
ment is a dense, fibrous connective tissue that attaches the
cementum of the tooth to the alveolar bone. It occupies a
narrow 0.1–0.25 mm [24] space between two calcified
structures, cementum and alveolar bone and is mainly made
up of collagen fibers (Type 1 and 3), vascular elements,
cells, and neural elements.
Periodontal disease
Diseases of the periodontium can be broadly classified as
either gingivitis or periodontitis. Gingivitis is an inflamma-
tion of the gingiva which manifests clinically with the usual
signs and symptoms of inflammation including an increase
in redness, swelling, bleeding, suppuration, and possible
pain. Deposits of dental plaque and calculus are often found
adherent to the tooth surface and in close contact with the
gingival margin. The primary etiology of virtually all
periodontal diseases is the bacterial biofilm termed dental
plaque that forms on tooth surfaces. Periodontal infections
are caused by anaerobic, gram-negative bacteria including
Aggregatibacter actinomycetemcomitans, Tannerella forsy-
thensis, Porphyromonas gingivalis, Prevotella intermedia,
Fusobacterium nucleatum, Campylobacter rectus, and
Treponema denticola. Although the primary etiology of
periodontal diseases is the bacterial biofilm that is present
on the surfaces of the teeth, these diseases are a result of a
complex interplay between the bacterial products and the
host response that are modified by behavioral and/or
systemic factors [25]. About 50% of the tissue destruction
associated with periodontal disease is attributed to host
response. The immune response that develops in response
to the chronic presence of plaque bacteria results in destruc-
tion of structural components of the periodontium, leading
ultimately, to the clinical signs of periodontitis. Page and
Schroeder [26] described the histopathogenesis of the lesion
of gingivitis in three stages: initial (2–4 days after bacterial
insult), early (4–7 days after) and established (14–21 days
after). The initial lesion is an acute vasculitis characterized
by vascular changes consisting essentially of dilation of
capillaries and increased vascular permeability with an
infiltration of polymorphonuclear leukocytes (PMNs) in the
space between the gingival margin and the tooth, in the
epithelium lining this space and in the subjacent connective
tissue. As the inflammatory lesion progresses to the next
stage, clinical signs of erythema may appear due to the pro-
liferation of capillaries and increased formation of capillary
loops. The epithelium lining the space between the tooth and
the gingival margin begins to proliferate into the subjacent
infiltrated connective tissue, and the inflammatory infiltrateFig. 3 Radiograph of healthy teeth and periodontium
Fig. 2 Diagrammatic representation of the different components of
the normal periodontium
Fig. 4 Gingival sulcus
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consists largely of lymphocytes and PMNs. Further altera-
tions in the histopathology of the lesion associated with
established gingivitis are consistent with the development
of a chronic inflammatory lesion, with the appearance of
numerous plasma cells, increased size of the inflammatory
infiltration of the connective tissue and increased vascular
changes wherein gingival blood vessels become engorged
and congested. The established lesion can be observed
clinically as moderate to severely inflamed gingiva
(Fig. 5). If left untreated, the established lesion progresses
to a fourth stage, which is the advanced lesion in which
destruction of connective tissue attachment to the tooth and
loss of supporting bone occurs.
Gingivitis is a common disease of the oral cavity. In the
third National Health and Nutrition Examination Survey
(NHANES III, 1988–94), 50% of the US adult population
was shown to have gingivitis on at least 4 teeth [27].
Although gingivitis is a fairly common disease and gingivitis
is a pre-requisite for periodontitis, not all sites with gingivitis
progress to periodontitis [28–31]. There are several factors
other than the amount of plaque accumulation that have
been shown to play a role in the progression of gingivitis to
periodontal disease. These include but are not limited to
age, pronounced inflammatory response, more pathogenic
bacteria, stress, genetic predisposition (IL-1 positive geno-
type individuals), and smoking status [32–34].
Periodontitis is an inflammatory disease of the gingiva
and the deeper periodontal tissues. Although periodontitis is
preceded and accompanied by gingivitis, gingivitis may
persist for indefinite periods without progressing to perio-
dontitis. Periodontitis involves destruction of gingival and
periodontal connective tissue fibers, resorption of tooth-
supporting bone, and apical proliferation of the junctional
epithelium resulting in the formation of deep pockets
between the gingiva and the tooth surface. These pockets
harbor pathogenic periodontal bacteria which are the
primary etiology of the periodontal lesion. If left untreated
this inflammatory lesion progresses, eventually leading to
loss of supporting structures of the teeth to the point that the
tooth is lost.
Clinically, patients with periodontitis demonstrate all or
some of the classical signs of inflammation seen in
gingivitis along with pocket formation and radiographic
bone loss (Fig. 6a and b). It is well documented that
moderate periodontal disease affects a majority of the adult
population, and is more severe in populations which do not
receive regular dental care [35, 36].
The histopathologic lesion of periodontitis is character-
ized by apical proliferation of junctional epithelium onto
cementum, lysis of collagen fibers of the periodontal
ligament, and bone destruction at the alveolar crest (Fig. 7).
There is an increase in the volume of the connective tissue
inflammatory infiltrate characterized by the presence of
PMNs, lymphocytes, macrophages, and plasma cells [26].
The interrelationship between periodontal disease
and diabetes
Epidemiologic studies have shown a three- to four-fold
increased risk for progressive periodontal destruction in
diabetic patients compared with individuals without diabetes
[37]. Although the biological basis for the relationship
between periodontitis prevalence and severity and the level
of metabolic control of diabetes has not been clearly
elucidated [46], there is ample clinical evidence to support
the view that poor glycemic control increases the risk in the
diabetic patient for more severe periodontal disease with
greater periodontal attachment loss, bone loss and deeper
periodontal probing depths [38–44] (Fig. 8).
Early research into the relationship between diabetes and
increased risk for periodontitis focused on potential differ-
ences in the bacterial microflora in diabetics versus non-
diabetics. The majority of this research shows, however that
the subgingival microbiota is very similar in diabetics and
non-diabetics with periodontal disease [45, 46]. Subsequent
research has been focused on differences in the immuno-
inflammatory response to periodontal pathogens in diabetic
versus non-diabetic subjects.
Multiple factors have been suggested to explain the
relationship between diabetes mellitus and periodontal
diseases including 1) altered immunoinflammatory response
to bacterial pathogens, 2) diminution of the formative aspects
of connective tissue metabolism, 3) impaired wound healing,
Fig. 5 Clinical presentation of
gingivitis. Inflammation is
localized to the gingiva and has
not spread to the bone
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4) microvascular changes and 5) formation of advanced
glycation end products [4]. Although the components of the
bacterial biofilm are similar in comparisons of dental plaque
samples from diabetic and non-diabetic patients [45–47], the
immuno-inflammatory responses to these bacterial patho-
gens are altered in the diabetic patient. Immune cell
functions such as adherence, chemotaxis and phagocytosis
have been shown to be impaired in neutrophils from diabetic
patients [48, 49]. In addition the monocyte / macrophage cell
line has been shown to be hyper-responsive to bacterial
antigens, particularly during episodes of hyperglycemia,
resulting in increased production of the proinflammatory
cytokines IL-1β and TNF-α [50, 51].
In addition to these altered immuno-inflammatory
responses, the formative aspects of connective tissue
metabolism appear to be diminished in the diabetic patient
and to be related to the level of metabolic control. Bone
turnover and osseous healing have been shown to be
impaired under the influence of hyperglycemia [52–55] due
to inhibition of osteoblastic cell proliferation and collagen
production [56–58]. In addition, studies have shown an
increased apoptotic response of fibroblasts and osteoblasts
to P. gingivalis infection in the presence of hyperglycemia,
resulting in a net decrease in the numbers of these matrix-
producing cells [59–61].
In addition to these inadequacies in the formative aspects
of connective tissue metabolism, hyperglycemia-induced
inhibition of the attachment and spreading of fibroblasts
[62] and microvascular changes [12, 13] all contribute to
impaired wound healing which is a common problem in the
diabetic patient. Characteristic microvascular changes asso-
ciated with diabetic complications, such as abnormal
growth and regeneration of blood vessels, have also been
described in the periodontal tissues [12–14]. Advanced
glycation end products (AGEs) have been shown to
accumulate in periodontal tissues in diabetic subjects [63]
and to play a role in these microvascular alterations. AGEs
bind irreversibly to collagen forming macromolecules which
Fig. 6 a. Clinical appearance of
periodontitis. Note gingival
inflammation, heavy deposit of
dental plaque and calculus and
gingival recession. b. The
radiograph from the same
patient shows advanced bone
loss and radiographic appear-
ance of calculus deposits
Fig. 8 Clinical presentation of periodontitis in patient with undiag-
nosed diabetes mellitus (type 1). History of multiple recurring
periodontal abscesses
Fig. 7 Histology of periodontitis lesion. Bacterial-induced inflamma-
tion has resulted in loss of connective tissue attachment to the tooth,
epithelial migration, pocket formation and loss of supporting bone
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accumulate in the basement membranes of endothelial cells
resulting in increased basement membrane thickness and
alteration in the normal homeostatic transport across the
membrane [42]. AGE production has also been associated
with increased production of vascular endothelial growth
factor (VEGF), a cytokine that is also involved in the
microvascular complications of diabetes [64, 65] and which
has been reported to be elevated in the gingival tissues of
diabetic patients [66].
The current knowledge about the relationship between
diabetes and periodontal diseases suggests a bidirectional
relationship between the two. Both diabetes mellitus and
periodontitis can be classified as chronic inflammatory
diseases although of different etiologic origin. Poorly
controlled diabetic subjects tend to present with more
severe periodontitis [67–70], and diabetic subjects with
untreated periodontitis generally have poorer metabolic
control of their diabetes [70–72]. Such studies suggest that
severe, long-standing inflammatory lesions in the untreated
patient with periodontitis could contribute to the exacerba-
tion of diabetes. In contrast, several studies have reported a
positive association between periodontal treatment and
improved metabolic control of diabetes mellitus [73–76].
Studies have suggested that an abnormal inflammatory
response known as a “hyper-inflammatory trait” occurs in
subjects with diabetes [77, 78]. This hyper-inflammatory
trait is characterized by an exaggerated secretion of
inflammatory mediators such as TNFα and IL-6 as well
as systemic markers of inflammation. Over time hypergly-
cemia in the diabetic patient leads to glycation of structural
proteins and lipids in the extracellular matrix and connec-
tive tissues as well as the vascular tissues [79–81]. These
vascular changes lead to disturbances in capillary function,
impaired perfusion of tissues and the release of reactive
oxygen species resulting in a systemic inflammatory chal-
lenge [82, 83]. In addition monocytes and endothelial cells
can interact with advanced glycation end products (AGEs)
via monocytic receptors (RAGE) to “prime” neutrophils and
macrophages resulting in increased secretion of cytokines
and inflammatory mediators by these cells. AGEs and
elevated unsaturated fatty acids which are often associated
with diabetes, are both capable of inducing a hypersecretory
monocytic state leading to an increased production of
inflammatory cytokines in response to antigenic or bacterial
stimulus [84–87]. Both periodontitis and diabetes mellitus
result in a systemic inflammatory challenge associated with
a chronic elevation of inflammatory mediators including
IL-1, TNFα, IL-6, PGE2, C-reactive protein, and fibrinogen
[83, 88, 89]. This hyper-inflammatory trait and the AGE-
RAGE upregulation of the inflammatory response to
bacterial antigens in the diabetic patient may result in a
more severe systemic inflammatory challenge and over-
expression of inflammatory mediators.
Given the fact that periodontal infections are associated
with a predominately gram negative bacterial etiology,
cytokines may also be secreted by cells in response to
stimulation by bacterial lipopolysaccharide. In this case
cytokine production occurs via a Toll-like receptor mediated
response resulting in secretion of cytokines IL-1β, IL-6, TNF-
α, and PGE2, all of which are implicated in the tissue
destruction associated with periodontitis [90, 91]. Infections
such as periodontitis result in elevated levels of circulating
cytokines including IL-1, TNFα, and IL-6. These cytokines
block lipoprotein lipase activity and induce hyperlipemia
[83, 92, 93]. TNFα promotes glycogenolysis and impairs
glucose uptake by cells leading to hyperglycemia [83, 93].
TNFα and IL-6 also target the hepatocyte and lead to
production of C-reactive protein [83, 92, 93]. The systemic
inflammatory challenge associated with both diabetes melli-
tus and periodontitis link diabetic metabolic dysregulation
and the severity of periodontal disease and shed light upon
the interactions between chronic oral and systemic inflam-
matory diseases.
Potential diagnostic components of gingival crevicular
fluid
As previously stated, both diabetes mellitus and periodon-
titis are chronic inflammatory diseases. As such, the
markers of inflammation that are common to diabetes and
periodontitis are an indication of disease control [94]. The
initiation and progression of an inflammatory lesion in the
periodontal tissues is positively associated with the flow of
gingival crevicular fluid (GCF) from the gingival sulcus or
periodontal pocket [95, 96] (Fig. 9). GCF is a serum
exudate that originates in the microcirculation of the
gingival tissues and flows into the gingival sulcus or
periodontal pocket carrying with it mediators of local tissue
destruction and byproducts of tissue metabolism [97]. Since
the 1980s numerous studies have attempted to identify
Fig. 9 Gingival crevicular fluid flow in a periodontal pocket
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components in the GCF which could aid in the identifica-
tion of specific periodontally involved sites which are in
active stages of tissue destruction [98], or to identify GCF
components which could be used to screen patients for
periodontitis or otherwise simplify periodontal examination
and diagnosis [99–102]. The composition of GCF some-
what mirrors that of plasma [99] and has, therefore been of
interest to clinicians as a less invasive medium to evaluate
for various systemic conditions including diabetes.
Glucose in GCF
Efforts to evaluate glucose levels in samples of blood from
the gingival sulcus or periodontal pocket during dental
examinations have been advocated as a method of expand-
ing the range of venues for diabetic screening due to the
fact that this method does not require a “finger stick” and
takes advantage of the presence of a blood sample that
would otherwise be discarded in the dental office [103].
Gingival bleeding is a common, virtually ubiquitous symptom
of gingivitis and periodontitis -a finding supported by the high
frequency of dental patients who report that their gingival
tissues routinely bleed when they brush and/or floss their
teeth. Likewise the gingival tissues of these patients bleed
during the gentle provocation of the tissues associated with a
routine dental and periodontal examination. Several studies
have shown that in diabetic subjects glucose levels in capillary
blood obtained from “finger sticks” correlate with glucose
levels from blood obtained from gingival sulci or periodontal
pockets during routine periodontal examinations [104–112].
Although early studies reported moderate to good correla-
tions between the glucose levels in gingival crevice blood
and capillary blood, the length of time required for collection
of samples and the need for special equipment and supplies
for sample collection and analysis made the use of gingival
blood samples cumbersome and inconvenient [104–106].
Parker et al. 1993 [113] tested the use of commercially
available reagent strips and an in-home glucose monitoring
device for the purpose of measuring glucose levels in
gingival crevicular blood and found that 92% of glucose
levels from gingival crevice blood samples were within
acceptable levels of measurement error compared to 90%
from capillary blood samples. More recent studies compar-
ing the glucose levels from gingival crevice blood and
capillary blood from finger sticks using in-home glucose
monitoring devices have reported high intra-patient correla-
tions using the Bayer Elite 2000 (r=0.98; p<0.0001) [108],
and the Xitux Diagnostics Smart-X self-monitoring blood
glucose device (r=0.997; p<0.0001) [107]. Contradictory
findings were reported in a test of the Freestyle\ Blood
Glucose Monitoring System wherein agreement between
measures of glucose level in gingival crevice and capillary
blood samples was low when the data was compared using
statistical measures of agreement/disagreement instead of
correlation/regression [109, 110]. Although it is possible that
part of the discrepancy in the literature over the validity of
glucose measurements in gingival crevice blood may be due
to the smaller volume of blood sampled from the gingival
crevice, studies have shown that glucose levels can be
reliably determined in sub-microliter volumes (0.2 to 0.8
microliter) of GCF and that GCF glucose levels are
significantly higher in periodontitis sites [114]. However,
no effort was made in this study to correlate or to determine
the level of agreement between measures of glucose levels
from GCF and serum glucose levels [114]. In a more recent
study Strauss et al. 2009 measured glucose levels from
gingival crevice and capillary finger-stick blood in an
OneTouch UltraMini Blood Glucose Monitoring System
and compared these measurements using both measures of
correlation and limits of agreement [103]. Samples were
taken from patients with established gingivitis and bleeding
on probing and compared with samples from patients with
minimal inflammation and little or no bleeding. In the
presence of frank gingivitis glucose levels in gingival crevice
and capillary blood were highly correlated (r=0.89) and the
limits of agreement were acceptable (−27.1 to 29.7). On the
other hand in the absence of gingivitis correlations between
the measures of glucose level were lower (0.78) and the
limits of agreement were much wider (−25.1 to 80.5). The
authors concluded that in the absence of frank gingivitis it
was difficult to obtain enough blood from the gingival
crevice for measurements without touching the tooth as the
tissues were manipulated to stimulate bleeding, possibly
resulting in contamination of the sample. Taken together
these studies suggest that samples of gingival crevice blood
taken during an initial, pre-treatment dental examination may
be used to screen previously undiagnosed patients for
diabetes using commercially available glucose monitoring
devices. However following dental and periodontal treatment
when gingivitis and bleeding on probing have been success-
fully controlled, it will be difficult to obtain a sufficient
volume of gingival crevice blood for reliable assessment of
glucose levels.
Structural proteins and proteolytic enzymes
The identification of biomarkers of periodontal disease
presence or active disease status has been a somewhat
elusive goal in periodontal research. Considerable effort has
been expended on the identification of some component of
the GCF which could identify a site or a patient at risk or
predict an impending episode of disease progression.
Research efforts have focused on the presence of tissue
specific structural molecules including collagen fragments
such as type 1 collagen carboxyterminal telopeptide, proteo-
glycans such as chondroitin sulfate, hyaluronan, heparin
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sulfate, osteonectin and bone sialoproteins [102], and on
regulators of tissue destruction such as collagenase and
matrixmetalloproteinases includingmatrixmetalloproteinase-
8 [101]. High levels of collagenase activity in GCF are
associated with degradation of periodontal tissues in destruc-
tive periodontitis. In this regard, Safkan-Seppälä [115]
evaluated GCF collagenase activity in poorly controlled
and well-controlled diabetics and healthy controls and found
that diabetic subjects had higher GCF collagenase activity
than healthy controls and that the collagenase activity was
related to the level of metabolic control. GCF levels of
lysosomal enzymes such as beta-glucuronidase and elastase,
and cytoplasmic enzymes such as lactate dehydrogenase
have also been studied for their potential as a biomarker of
periodontal destruction. Lamster et al. [99] reported a
clinical study wherein GCF levels of beta-glucuronidase,
but not lactate dehydrogenase were predictive of periodontal
breakdown. Palcanis et al. [100] showed that GCF levels
of elastase were significantly higher at sites which demon-
strated periodontal bone loss in subsequent examinations
over a six month period. More recently, Gursoy et al. [116]
investigated the periodontal status and aspartate aminotrans-
ferase and lactate dehydrogenase enzyme activities in GCF
of type 2 diabetic and/or obese chronic periodontitis patients,
comparing these to healthy controls. Although the periodon-
tal status was worse in subjects with diabetes, no significant
differences in aspartate aminotransferase and lactate dehy-
drogenase enzyme activities were observed. Although the
search continues for an appropriate biomarker in the GCF
associated with periodontal disease presence and progres-
sion, most of the current research is focused on studies of
various immuno-inflammatory proteins including cytokines,
inflammatory mediators and growth factors.
Inflammatory mediators in GCF
GCF levels of IL-1β are known to be high in subjects with
periodontitis [117–120], and even more so in subjects with
diabetes [121–125]. Salvi et al. [121] compared the GCF
levels of IL-1β, PGE2 and TNF-α in diabetics and
systemically healthy subjects with varying degrees of
periodontal disease severity and found that diabetics had
significantly higher GCF levels of both PGE2 and IL-1β
when compared to non-diabetic controls with similar
periodontal status. In addition GCF levels of IL-1β and
PGE2 increased in diabetics as the severity of periodontal
disease increased. Engebretson et al. [123] investigated the
effects of glycemic control on GCF levels of IL-1β in
patients with chronic periodontitis and type 2 diabetes and
found that clinical periodontal measures and measures of
glycemic control (HbA1c, random glucose) were signifi-
cantly correlated with GCF IL-1β. Patients with greater
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levels than patients with less than 8% HbA1c. Andriankaja
et al. [125] compared the levels of serum IL-6 and GCF
IL-1β and PGE2 in subjects with gingivitis and type 2
diabetes. GCF IL-1β was significantly elevated in the
diabetic compared to the non-diabetic group but serum IL-6
and GCF PGE2 were not. GCF IL-1β and PGE2 levels were
significantly elevated in subjects with gingivitis compared
to subjects with gingival health regardless of diabetic status.
However, serum IL-6 was elevated in subjects with gingivitis
compared to healthy subjects only among those subjects with
diabetes. Kardeşler et al. [126] investigated the relationship
of periodontal disease in type 2 diabetics with GCF levels
of PGE2 and IL-1β and in contrast to most studies, found
lower IL-1β levels in the type 2 diabetic group, and
similar levels of PGE2 in diabetic and non-diabetic
periodontitis patients. In general most studies report
elevated levels of IL-1β in GCF from diabetic patients
and increased expression of IL-1β as the severity of
periodontal inflammation increases which is consistent
with the hypothesis that hyperglycemia contributes to an
heightened inflammatory response, and suggests a mech-
anism to account for the association between poor
glycemic control and periodontal destruction (Table 1).
Hyperglycemia-induced activation of the protein kinase
C pathway leads to increased expression of vascular
endothelial growth factor (VEGF) which can alter vascular
permeability and angiogenesis. The increased concentration
of VEGF in periodontitis [127, 128] may be one of the
reasons for the increased vascularization and permeability
associated with periodontitis, and it may be regarded as a
marker for disease severity. Prapulla et al. [128] compared
GCF VEGF levels in gingivitis and periodontitis patients
and healthy controls and found that VEGF levels in GCF
increased from health to periodontitis, and that periodontal
treatment resulted in a reduction of GCF VEGF levels. The
authors suggested that VEGF could be considered a biomarker
of periodontal disease progression. Sakallioğlu et al. [129]
studied gingival tissue and GCF VEGF levels in diabetic
periodontitis patients with good metabolic control compared
to that of systemically healthy patients with periodontitis.
This study found significantly higher VEGF levels in the
gingival tissue supernatants of the diabetic group, but GCF
VEGF levels were similar between the controlled diabetic
and the systemically healthy subjects.
Prostaglandin E2 (PGE2) is associated with periodontal
disease progression and alveolar bone resorption [130].
Levels of GCF PGE2 are elevated in the presence of
periodontitis and perhaps even more so in diabetic patients
[121]. Offenbacher et al. [131] reported significant increases
in GCF PGE2 levels a few months prior to clinically evident
progression of periodontal attachment loss and suggested
that monitoring of GCF PGE2 levels could be of value in
predicting episodes of periodontal disease progression
enabling the administration of preventive therapy before
the onset of tissue destruction. More recent studies of GCF
PGE2 levels in diabetic patients have, however cast some
doubt on the usefulness of this agent as biomarker of disease
progression. Kardesler et al. [126] observed that GCF PGE2
levels in diabetics were higher than healthy controls when
levels were expressed as total amount of PGE2. When GCF
PGE2 levels were expressed as concentration of PGE2 the
concentration of PGE2 was lower in GCF from diabetic
subjects. These findings suggest that the differences in GCF
PGE2 levels are more a function of increased volume of
GCF in the diabetic rather than an increased expression of
PGE2. Andriankaja et al. [125] compared GCF PGE2 levels
in diabetics and healthy controls during the development of
experimental gingivitis, and found that GCF PGE2 levels
increased with the presence of gingivitis, but that the amount
of GCF PGE2 was similar in diabetics and healthy controls
(Table 1).
Hyperglycemia-induced activation of the protein kinase
C pathway also results in increased expression of trans-
forming growth factor (TGF)-β which leads to changes in
collagen and fibronectin thereby promoting capillary
occlusion. Gurkan et al. [132] measured GCF TGF-β1 in
several forms of periodontal disease and found that GCF
levels of TGF-β1 were significantly elevated in subjects
with periodontitis compared to healthy controls and that
GCF TGF-β1 levels were correlated with all clinical peri-
odontal parameters. Schierano et al. [133] measured TNF-α,
TGF-β2 and IL-1β levels in GCF before and after the onset
of experimental gingivitis in non-diabetic subjects. Although
the volume of the crevicular fluid and the GCF levels of IL-
1β increased significantly with the onset of gingivitis, TNF-α
and TGF-β2 levels in GCF did not change significantly. GCF
expression of transforming growth factor in diabetic perio-
dontitis patients has not been reported (Table 1).
Other inflammatory mediators which have been studied
as potential biomarkers of periodontal disease include IL-
1α, IL-6, IL-8, IL-18, Interferon-α, and TNF-α (Table 1).
GCF levels of IL-1α have been shown to be increased in
the presence of gingivitis and periodontitis [134–136] and
to decrease following periodontal treatment [134, 136]. No
studies of GCF levels of IL-1α in diabetic subjects have
been reported. Kurtis et al. [137] compared GCF levels of
IL-6 in diabetics and healthy controls with and without
periodontitis. The concentration of IL-6 in GCF was higher
in periodontitis than in healthy gingival sulci, and was
higher in diabetic patients than that of both healthy controls
and non-diabetic patients with periodontitis. GCF levels of
IL-8 [119, 135, 138], IL-18 [120] and Interferon-α [135]
have also been shown to increase in the presence of
gingivitis and periodontitis. In addition the GCF levels of
IL-8 have been shown to decrease following periodontal
treatment [119]. However, no studies of GCF levels of IL-8,
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IL-18 or Interferon-α in diabetics have been reported
(Table 1).
Studies have also investigated the potential of various
components of saliva for diagnosing and evaluating the
prognosis and evolution of diabetes mellitus and its oral
manifestations. Borg Andersson et al. [139] studied the
glucose content of parotid saliva and found that salivary
levels of glucose peaked at two hours following a glucose
challenge and was significantly elevated in subjects with
impaired glucose tolerance or diabetes mellitus, but not in
healthy controls. Arana et al. [140] compared markers of
oxidative stress in saliva from patients with type 2 diabetes
mellitus with that of healthy controls and found signifi-
cantly higher glutathione peroxidase and glutathione reduc-
tase activity, and significantly lower reduced glutathione in
diabetic subjects. More recently Gumus et al. [141] also
reported significantly lower reduced glutathione in diabetic
subjects, but only in type 1 diabetics, and no other
differences in the levels of other salivary antioxidants were
observed. Possible explanations for the differences in the
findings of these studies may include the fact that
stimulated saliva samples were employed in one study
[140], while unstimulated samples were evaluated in the
other [141]. In addition, the prevalence and severity of
periodontal disease differed somewhat between the two
studies, as well as the methods used to diagnose and
describe the degree of periodontal involvement.
Conclusion
In view of the fact that diabetes mellitus and periodontitis
share many features consistent with chronic inflammatory
disorders, it is reasonable to pursue the identification and
utility of biomarkers of disease status that are common to
these diseases, and that can be used to evaluate a patient’s
disease status and better design intervention strategies.
Studies in diabetic patients have indicated that the ex vivo
quantification of gelatinase activity in serum and the
expression of recoverin in mononuclear blood cells were
useful for the prediction of active proliferative retinopathy,
suggesting that diabetic patients might be monitored for the
expressions of these molecules for more effective timing of
appropriate therapy [150]. Studies conducted to date
suggest that gingival crevicular fluid may be an acceptable
substitute for “finger stick” blood for determination of
serum glucose levels and may therefore be a useful
screening tool in the dental office. Although considerable
effort has been applied in the attempt to identify an
immuno-inflammatory biomarker for these diseases, the
ideal biomarker has yet to be found. Some of the promising
inflammatory cytokines and growth factors that are
expressed in the GCF as a part of the host response and
that have been shown to be elevated in both periodontitis
and diabetes include IL-1β, IL-6, PGE2, and VEGF.
However, none of these agents have been shown to be a
valid biomarker due to inconclusive, conflicting or insuffi-
cient data. Although we have known for some time that the
presence of these cytokines are increased in the GCF during
infection and inflammation, it has been hard to quantify this
association in terms of determining the extent to which the
quantity of the expressed cytokine goes up or down with
changes in inflammation. Further research is necessary to
clarify the usefulness of these potential biomarkers and to
likewise investigate additional cytokines which have yet
to be studied in this regard.
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